Insights on the Allergy Immunotherapies Global Market to 2028: Rising Awareness of Allergy Immunotherapies, Elevating Income Levels and Increasing Healthcare Expenditure Drives Growth
21 févr. 2023 13h18 HE
|
Research and Markets
Dublin, Feb. 21, 2023 (GLOBE NEWSWIRE) -- The "Allergy Immunotherapies Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028" report has been added to ...
BioAegis Therapeutics Announces FDA Clearance of IND for its ‘Inflammation Regulator Protein,’ Gelsolin, for the Treatment of ARDS
26 janv. 2023 14h05 HE
|
BioAegis Therapeutics
NORTH BRUNSWICK, N.J., Jan. 26, 2023 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, Inc., a clinical-stage company developing therapies for inflammatory diseases through a portfolio built around plasma...
BioMed X and AbbVie Extend Research Collaboration in the US
16 janv. 2023 13h00 HE
|
BioMed X Institute
HEIDELBERG, Germany, Jan. 16, 2023 (GLOBE NEWSWIRE) -- BioMed X, an independent German biomedical research institute, announced today the extension of its ongoing research collaboration with AbbVie....
Derm-Biome Pharmaceuticals’ Multi-Target Topical Drug Produces Positive Results in Preclinical Study in Acne
09 janv. 2023 10h00 HE
|
Derm-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals, Inc, a Vancouver based biopharmaceutical company focused on skin health, is pleased to announce that in a...
BioAegis Leverages Gelsolin’s Broad Therapeutic Applicability by Expanding into Multiple Inflammatory Diseases
06 janv. 2023 14h50 HE
|
BioAegis Therapeutics
NORTH BRUNSWICK, N.J., Jan. 06, 2023 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, Inc., a clinical-stage company developing therapies for inflammatory diseases through a portfolio built around plasma...
Global Inflammatory Bowel Disease Treatment Market Research Report 2022 Featuring AbbVie, Biogen, Johnson & Johnson, Amgen, & UCB SA
08 nov. 2022 06h13 HE
|
Research and Markets
Dublin, Nov. 08, 2022 (GLOBE NEWSWIRE) -- The "Inflammatory Bowel Disease Treatment Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.The global inflammatory...
Evelo Biosciences to Present at the 2022 Jefferies London Healthcare Conference
08 nov. 2022 06h00 HE
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting on...
Arch Biopartners Adds Dr. David Luke as a Strategic Advisor, Clinical Trials
05 août 2022 07h30 HE
|
Arch Biopartners
TORONTO, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company targeting acute organ inflammation with...
Evelo Biosciences to Announce Second Quarter 2022 Financial Results on Thursday, August 11, 2022
05 août 2022 06h00 HE
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., Aug. 05, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting on...
Evelo Biosciences Announces Appointment of Marella Thorell as Chief Financial Officer
18 juil. 2022 06h00 HE
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., July 18, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting on...